Repurposing old weapons for new battles

Using disulfiram (Antabuse) to fight cancer

Go to the profile of Luke Hoeppner
Jan 02, 2018
1
0

It’s a typical Tuesday night. You’re sitting on your couch watching TV and that commercial touting the latest and greatest new prescription drug plays for seemingly the fifth time tonight…

“Wow, why does the pharmaceutical industry invest so much money in advertising?”

Because bringing a new drug to market is a long and arduous road:

  • The average time from drug target identification to FDA approval is about 13 years.
  • Failure rates can be as high as 95%.
  • The cost of bringing a new drug to market exceeds $500 million. That figure tops $1 billion when accounting for failed drugs.

The strategy of drug repurposing - discovering new uses for old drugs- overcomes current barriers of drug development by relying on previous research efforts.

Drug repurposing examples include:

  • Metformin: A popular diabetes drug that has been shown to reduce the risk of breast cancer as well as some other types of cancer.
  • AZT: A failed anti-cancer treatment was the first drug used to treat HIV patients.
  • Celecoxib: A drug used to treat osteoarthritis by inhibiting a molecular pathway associated with inflammation has been shown to reduce the risk of additional polyp formation in colon cancer patients.

A drug with long history as a treatment for alcohol dependence was found to have anti-cancer effects. Disulfiram (commercially known as Antabuse) makes people feel sick after consuming a small amount of alcohol. An early 1970s case report detailed a breast cancer patient with tumors that had spread to her bones who became an alcoholic and ceased cancer treatment, yet received disulfiram to discourage drinking alcohol. After a fatal inebriated fall, an autopsy of the woman surprisingly showed that nearly all the cancer in her bones had disappeared.

This finding ignited excitement. Subsequent animal studies showed disulfiram killed cancer cells and slowed tumor growth. A small 1993 clinical trial reported disulfiram increased survival in women who had breast tumors removed. Despite its promise, scientists have been unable to explain how this drug inhibits cancer, which has lessened enthusiasm and ultimately prevented disulfiram from translating to use in the clinic as an anti-cancer treatment.

Recently, Dutch researchers solved the mystery by identifying the molecular target of disulfiram’s tumor-suppressing effects.  Examining a cohort of over 3000 cancer patients, they confirmed that cancer patients who continued taking disulfiram (Antabuse) showed increased survival, as compared to patients who stopped taking the drug. Cancer biologist, Dr. Jiri Bartek, and other researchers also worked out how the drug kills cancer cells. They showed that the primary metabolite of disulfiram (i.e. ditiocarb) forms a complex with copper that prevents cells from properly destroying misfolded and “waste” proteins. The resulting cellular buildup of proteins causes stress, which promotes tumor cell death.

Specifically, disulfiram inhibits protein degradation orchestrated by the p97 pathway. This is important because previous studies have demonstrated that high levels of p97 correlate with the progression and spread (metastasis) of breast, colon and prostate cancers. Thus, disulfiram may represent a promising precision oncology treatment for patients whose cancers have high levels of the p97 protein.

To view the recent original Nature paper, please use the link below:

https://www.nature.com/articles/nature25016

To read more about it in the news, please refer to:

http://www.sciencemag.org/news/2017/12/old-drug-alcoholism-finds-new-life-cancer-treatment?utm_source=sciencemagazine&utm_medium=facebook-text&utm_campaign=olddrug-16758

 

 

 

Go to the profile of Luke Hoeppner

Luke Hoeppner

Assistant Professor, The Hormel Institute, University of Minnesota

Our current research directions include studying angiogenesis, tumor microenvironment, lung cancer, vascular permeability, and skin biology.

No comments yet.